1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. CIPLA LTD.
Cipla Ltd.
NSE: CIPLA | BSE: 500087

Cipla Live Share Price Today, Share Analysis and Chart

Mid-range Performer
BasketIn 4 Starfolio Baskets
aboutCipla Ltd. is a global pharmaceutical company focused on making affordable medicines accessible. It holds a leading position in the Indian pharmaceutical market (IPM) and has a significant presence in South Africa and the US. The company’s core offer... Read More
US FDA InspectionsANDA Approvals
Ask AI about Cipla
1378.9020.90(1.54%)
1.5M
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
50.6 / 100
Mid-range PerformerThese stocks have average quality, financial and technical momentum, indicating a mid range performerView SimilarEmbed DVM
Analyst Price Target
-

15

S

8

W

10

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

12Positive11Negative

Pass in checklist52.2%

045
55
100

PE Valuation Check

Right Now
Overvalued
-23%
1 Year Forward
Fairly Valued
4.8%
INSIGHTCipla is overvalued at current PE, but fairly valued on future earnings estimates

Cipla Stock Price Analysis

Day Price Range

1.5% 1 Day return
1378.9 (LTP)
1,3571,381.7
LowHigh

Week Price Range

3.1% 1 Week return
1378.9 (LTP)
1,3191,381.7
LowHigh

Month Price Range

-0.0% 1 Month return
1378.9 (LTP)
1,2921,384
LowHigh

52 Week Price Range

-10.5% 1 Year return
1378.9 (LTP)
1,165.71,539.7
LowHigh
View full Price History/Seasonality

Cipla Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Cipla's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
48
AVG. ESTIMATE
48.8
LOW ESTIMATE
44.7
HIGH ESTIMATE
53.1
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 1.6% in FY27

Consensus Recommendation

36 ANALYST Recommendations
BUY

The consensus recommendation from 36 analysts for Cipla is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Cipla Technical Analysis

Cipla EMA & SMA

Bullish+4
6 bullish, 2 bearish
Bullish6
Bearish2
5 Day1361.2
10 Day1350.8
12 Day1348.8
20 Day1347.9
26 Day1350.9
50 Day1365.8
100 Day1379.4
200 Day1394.1

Cipla Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202655.3%
Week45.7%
Month55.2%

Cipla Active Candlesticks

Closing Marubozu Uptrend Long Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Cipla Resistance and Support

1372.53
Pivot
First Resistance1388.1
Second Resistance1397.2
Third Resistance1412.8
First Support1363.4
Second Support1347.8
Third Support1338.7
Day RSI59.2
Day MACD-2.1
Day MFI61.8
Day MACD Signal Line-10.5

Cipla Beta

1 Month0.5
1 Year0.5
3 Month0.5
3 Year0.5

Cipla Price Change Analysis

↓0.0%
Over 1 Month
LowHigh
12921384
↓-6.0%
Over 3 Months
LowHigh
12921488.1
↑4.7%
Over 6 Months
LowHigh
1274.71491.2
↓-10.5%
Over 1 Year
LowHigh
1165.71539.7
All Technicals →

Cipla Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Yusuf Khwaja HamiedPromoter150,521,18318.7 %
Government Pension Fund GlobalFii9,899,7671.2 %
Lici Ulip-Growth FundDii77,271,8419.6 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Cipla Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GOLDMAN SACHS (SINGAPORE) PTE.- ODIBlockSell16 Oct 2025156591,604NSE
GOLDMAN SACHS BANK EUROPESE - ODIBlockPurchase16 Oct 2025156591,604NSE
THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828BlockSell14 Jul 20251485156,532NSE
THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849BlockPurchase14 Jul 20251485156,532NSE
RUMANA HAMIEDBlockSell02 Dec 20241518.754,943,250NSE
SAMINA HAMIEDBlockSell02 Dec 20241518.758,954,750NSE
SOCIETE GENERALEBlockPurchase02 Dec 20241518.75216,967NSE
SBI LIFE INSURANCE COMPANY LIMITEDBlockPurchase02 Dec 20241518.75611,969NSE
TATA AIA LIFE INSURANCE COMPANY LIMITEDBlockPurchase02 Dec 20241518.75322,676NSE
ADITYA BIRLA SUN LIFE MUTUAL FUNDBlockPurchase02 Dec 20241518.75600,847NSE
All deals
All insider trades

Cipla Corporate Actions

Cipla Dividend history and yield

Cipla dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Cipla dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
105 Jun 2026
13FINAL05 Jun 2026Equity Share
227 Jun 2025
3SPECIAL27 Jun 2025Equity Share
327 Jun 2025
13FINAL27 Jun 2025Equity Share
402 Aug 2024
13FINAL02 Aug 2024Equity Share
521 Jul 2023
8.5FINAL21 Jul 2023Equity Share

Cipla Bonus shares

Cipla bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
124 Apr 2006
3:225 Apr 2006

Cipla Board Meetings

Cipla past and upcoming board meetings.

#Ex-Date
PurposeNotes
127 Oct 2026
Quarterly Results-
223 Jul 2026
Quarterly Results-
313 May 2026
Audited Results & Final Dividend-
423 Jan 2026
Quarterly Results-
530 Oct 2025
Quarterly Results-

Cipla Stock Split

Cipla stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
111 May 2004
10219 May 2004

Cipla Rights issue

Cipla rights issue history, along with record, ex-rights dates, and rights ratios.

#Ex-Date
RatioFace ValuePremiumRecord Date
103 Feb 1995
4.0:50.0-66002 Mar 1995
All Corporate Actions

Cipla Research Reports

Cipla research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
127 Oct 2026ICICI Securities Limited16101365.6Buy17.9%0.97%pdf
226 Oct 2026Motilal Oswal
Target
14501350Neutral7.41%2.14%pdf
326 Jul 2026Deven Choksey
Target
15921410.6Accumulate12.86%-2.25%pdf
423 Jul 2026ICICI Securities Limited
Target
16101393Buy15.58%-1.01%pdf
523 Jul 2026Axis Direct15321410.6Buy8.61%-2.25%pdf
All Reports of Cipla

Cipla Corporate Filings

Cipla BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
30 Oct 2026
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find enclosed Earnings Call Transcript - Q2FY27
PDF
29 Oct 2026
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 29th October, 2026 has allotted 17,453 fully paid up equity shares of INR 2 each pursuant to exercise of stock options/ stock appreciation rights under the Employee Stock Option Sceheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021.
PDF
28 Oct 2026
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed newspaper intimation for financial results for the quarter and half year ended 30th September, 2026.
PDF
27 Oct 2026
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the earnings conference call for the quarter and half year ended 30th September, 2026 held today is available on the Company's website at https://www.cipla.com/audio/15120.
PDF
27 Oct 2026
Cipla Ltd. Results Earnings Call for Q2FY27
Conference Call with Cipla Ltd. Management and Analysts on Q2FY27 Performance and Outlook. Listen to the full earnings transcript.
PDF
VIEW ALL

Cipla DocumentsAsk MarketMind AI

Cipla Earnings Call

Cipla earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
30 Oct 2026Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
27 Oct 2026Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
27 Oct 2026Cipla Ltd. Results Earnings Call for Q2FY27AudioVideo
27 Jul 2026Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
23 Jul 2026Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
view all

Cipla Annual Reports

Cipla financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Cipla Credit Ratings

Cipla credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
09 Sep 2026care ratingsCipla LimitedLink
18 Dec 2025india ratingsIndia Ratings Affirms Cipla at ‘IND AAA’/Stable and its CP at ‘IND A1+’Link
25 Aug 2025care ratingsCipla LimitedLink
19 Dec 2024india ratingsIndia Ratings Affirms Cipla at ‘IND AAA’/Stable and its CP at ‘IND A1+’Link
07 Oct 2024care ratingsCipla LimitedLink

Cipla Investor Presentations

Cipla investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
27 Oct 2026Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
23 Jul 2026Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
13 May 2026Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
23 Jan 2026Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
30 Oct 2025Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Cipla - Company Profile

Cipla Management Structure

Cipla management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Ms. Sneha HiranandaniChief Information Officer-Mar 26
Ms. Meera VanjariChief General Counsel-Mar 26
Mr. Sai MungaraGlobal Head(Supply Chain.)-Mar 26
Mr. Paul MillerChief Executive Officer(South Africa),Regional Head(Africa,Access)-Mar 26
Mr. Marc FalkinChief Executive Officer-Mar 26
Mr. Sushrut KulkarniGlobal Chief(Integrated Product Development)-Mar 26
Mr. Vijayasarathi RamaswamiGlobal Chief Quality Officer,Global Head(Quality)-Mar 26
Mr. Venkata Sai MungaraGlobal Head(Supply Chain.)-Mar 26
Mr. Swapn MalpaniChief Executive Officer(Emerging Markets)-Mar 26
Achin GuptaManaging Director,Global Chief Executive Officer,Global Chief Operating Officer-Mar 26
Mr. Sanjay Varughese JosephHead(API Business)-Mar 26
Rajendra ChopraCompany Secretary,Compliance Officer-Mar 26
Mr. Prabhakaran Balakrishnan NairChief Manufacturing Officer-Mar 26
Mr. Jaideep GogtayChief Medical Officer-Mar 26
Ms. Heena KanalChief(Corporate Communication.)-Mar 26
Mr. Deepak ViegasChief Internal Auditor-Mar 26
Mr. Ashish AdukiaGlobal Chief Financial Officer-Mar 26
Mr. Arun KakatkarGlobal Chief People Officer-Mar 26

Cipla Board of Directors

Cipla Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Adil ZainulbhaiNon-Exec & Non-Independent Dir265Mar 26
Kamil HamiedNon-Exec & Non-Independent Dir263Mar 26
Abhijit J. JoshiNon-Exec & Non-Independent Dir259Mar 26
Y K HamiedChairman & Non Executive Dir.258Mar 26
P R RameshVice Chairman / Independent Non Executive Director110Mar 26
MAYA HARIIndependent Non Exe. Director110Mar 26
SHARMILA NITIN PARANJPEIndependent Non Exe. Director98Mar 26
Mandar Purushottam VaidyaIndependent Non Exe. Director93Mar 26
Dr Balram BhargavaIndependent Non Exe. Director92Mar 26
Achin GuptaMD / Global CEO / Global COO-Mar 26
Rajendra ChopraCompany Sec. & Compli. Officer-Mar 26
Rashmi JoshiAdditional Director-Mar 26

Cipla Brands

Brands owned by Cipla

LOGOBRAND NAME
Ciplactin
Nutrolin-B Dry Syrup
Asthalin Inhaler
Norflox Tz
LOGOBRAND NAME
Imusporin
Cipril-H
Amlopres-At
Acivir Dt
LOGOBRAND NAME
Viraday
Antiflu
Erlocip
Soranib
LOGOBRAND NAME
Linospan
Zolmist
ticocin
Endobloc
Website: www.cipla.com

About the company - Business Profile

Cipla Ltd. is a global pharmaceutical company focused on making affordable medicines accessible. It holds a leading position in the Indian pharmaceutical market (IPM) and has a significant presence in South Africa and the US. The company’s core offerings span across various therapeutic areas, with a dominant stance in respiratory, anti-infectives, and cardiac care.

Key Points

  • Key Facts: Founded in 1935 by Dr. K.A. Hamied, Cipla is headquartered in Mumbai, India. It is a publicly listed company on the BSE and NSE.
  • Operations and Resources: The company operates a vast network of manufacturing facilities and R&D centers globally. Notably, it has unlocked capacity at its China respules facility and operates Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) sites in the U.S.
  • Ownership: As of March 31, 2024, the Promoter and Promoter Group held 33.40% of the total shares. Key individual shareholders include Dr. Y.K. Hamied (18.64%) and Ms. Sophie Ahmed (5.70%).
  • Market Significance: Cipla ranks 2nd in the South African prescription market and holds a top position in the U.S. Albuterol MDI market. It serves critical healthcare needs globally through its "Caring for Life" philosophy.
  • Sustainability and Innovation: Cipla has committed to achieving Net Zero by 2050. Near-term goals for 2030 include an 80% renewable electricity share for India manufacturing and a 30% absolute reduction in GHG emissions (Scope 1 and 2) from an FY 2024 baseline.
  • Business Model: The company follows a vertically integrated model, excelling in complex generics, particularly inhalation therapies. It focuses on high-margin chronic therapies, which accounted for 61.5% of its branded prescription sales in FY 2025.
  • Revenue Breakdown (FY 2024-25):
    • By Geography: One India (45%), North America (24%), Emerging Markets (12%), Europe and Key Accounts (8%), and Others (11%).
    • By Therapy: Respiratory (22%), Cardiovascular (19%), Oncology (15%), Gastrointestinal (8%), Central Nervous System (12%), and Others (24%).
  • Key Products and Technology:
    • Respiratory: Strong leadership in MDIs and DPIs.
    • Peptides: Launch of four peptide products, including Liraglutide, planned by FY 2027.
    • Biosimilars: Strategic investments in oligonucleotides and differentiated 505(b)(2) products.
  • Partnerships: The company actively collaborates with global innovators and maintains a PEPFAR-approved ANDA portfolio for international access programs.
  • Employee Trends: Managed by a global leadership team, including CEO One India Business Achin Gupta and Global Chief People Officer Dr. Raju Mistry.
  • Strategic Initiatives: Future outlook focuses on expanding the peptide and injectable pipeline, scaling the consumer health business (Cipla Health Limited), and increasing the share of chronic therapies in the Indian market.

References

  1. Annual Report May 2025
  2. Investor Presentation Jan 2026
  3. Investor Presentation Oct 2025
  4. Annual Report May 2024

Cipla FAQ

Cipla today is trading in the green, up by 1.54% at ₹1,378.9.
Cipla is currently trading up 1.54% on an intraday basis. In the past week the stock rose 3.06%. Stock has been down 5.97% in the past quarter and fell 10.47% in the past year. You can view this in the share price history/seasonality section.
Cipla is listed on NSE with the ticker CIPLA and on BSE as 500087. It's currently trading on NSE at a share price of ₹1,378.9 and on BSE with a share price of ₹1,380.
The market cap of Cipla is ₹111,399.69 Cr. as of Oct 30, 2026.
Cipla announced a FINAL dividend of 650% which equals ₹13 in Jun 05, 2026.The last three ex-dates for Cipla were Jun 27, 2025, Jun 27, 2025 and Aug 02, 2024. To view the full dividend history of Cipla click here.
Cipla has undergone 1 stock split and announced bonus shares 1 time since its BSE/NSE listing. The latest announcement for Cipla stock split was on May 11, 2004 at a ratio of 10:2 and the last bonus share announcement was on Apr 24, 2006 at a ratio of 3:2.
Cipla reported ₹7,555.09 Cr. in revenue, ₹877.54 Cr. in net profit, and ₹1,538.94 Cr. in EBITD as of Oct 27, 2026 for Q2 FY26-27.
According to the predictions of 36 analysts, the share price prediction for Cipla is ₹1,504.81 with an upside of 9%.
The PE ratio of Cipla is 38.45 as of Oct 30, 2026.
The PB ratio of Cipla is 3.16 as of Oct 30, 2026.
You can view the latest analyst reports on the Cipla reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×